We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Increased Protection of Earlier Use of Immunoprophylaxis in Preventing Perinatal Transmission of Hepatitis B Virus.
- Authors
Huang, Hongyu; Xu, Chenyu; Liu, Lanhua; Chen, Liping; Zhu, Xiaoqin; Chen, Jie; Feng, Jing; Chen, Tingmei; Xu, Biao; Yang, Jishi; Xu, Biyun; Pan, Mingjie; Dai, Yimin; Hu, Yali; Zhou, Yi-Hua
- Abstract
Background Passive-active immunoprophylaxis against mother-to-child transmission (MTCT) of hepatitis B virus (HBV) recommends administering hepatitis B immunoglobulin (HBIG) and birth-dose hepatitis B vaccine in infants within 12 or 24 hours after birth. With this protocol, MTCT of HBV still occurs in 5–10% infants of HBV-infected mothers with positive hepatitis B e antigen (HBeAg). The present study aimed to investigate whether earlier administration of HBIG and hepatitis B vaccine after birth can further increase protection efficacy. Methods We conducted a prospective, multi-center observational study in infants born to mothers with HBV infection, in whom neonatal HBIG and birth dose hepatitis B vaccine were administered within one hour after birth. The infants were followed up for HBV markers at 7–14 months of age. Results A total of 1140 pregnant women with HBV were enrolled, and 982 infants (9 twins) of 973 mothers were followed up at 9.6 ± 1.9 months of age. HBIG and birth-dose vaccine were administered in newborn infants within a median of 0.17 (0.02–1.0) hours after birth. The overall rate of MTCT was 0.9% (9/982), with none (0%) of the 607 infants of HBeAg-negative mothers and 9 (2.4%) of 375 infants of HBeAg-positive mothers acquiring HBV. All 9 HBV-infected infants were born to mothers with HBV DNA >2.75 × 106 IU/mL. Maternal HBV DNA levels >2 × 106 IU/mL were an independent risk factor (odds ratio, 10.627; 95% confidence interval, 2.135–∞) for immunoprophylaxis failure. Conclusions Earlier use (within 1 hour after birth) of HBIG and hepatitis B vaccine can provide better protection efficacy against MTCT of HBV.
- Subjects
CHINA; HEPATITIS B prevention; DNA analysis; RESEARCH; IMMUNOGLOBULINS; SCIENTIFIC observation; CONFIDENCE intervals; MEDICAL cooperation; PREGNANT women; TREATMENT effectiveness; RISK assessment; DESCRIPTIVE statistics; HEPATITIS B vaccines; ODDS ratio; VERTICAL transmission (Communicable diseases); LONGITUDINAL method
- Publication
Clinical Infectious Diseases, 2021, Vol 73, Issue 9, pe3317
- ISSN
1058-4838
- Publication type
Article
- DOI
10.1093/cid/ciaa898